Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.

Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.

Abstract: A system for testing a vapor product with a mouthpiece that has a non-circular cross section includes an adaptor coupled to a neck portion of a filter pad holder. The adaptor includes a nose to receive the neck portion and an adaptor body coupled to the nose. An opening is defined by the adaptor body and the nose, the opening extending through the adaptor body and the nose and configured to receive the neck portion. A sealing member is configured to be received by the adaptor and the filter pad holder. The sealing member includes a sealing member nose configured to be received by the neck portion, and a sealing member body coupled to the sealing member nose and configured to be received by the opening. The sealing member body defines an orifice, the orifice extending through the sealing member body.

Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.

Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.

Abstract: A connector in an electronic nicotine delivery systems (“ENDS”) device, including aerosol delivery devices such as smoking articles that produce aerosol, may include multiple concentric pins, which each have multiple contact points for providing a more reliable connection and for preventing disruptions that may be caused from improper contacts. The connection may be between a cartridge and a battery portion of the aerosol delivery device or with a product use and behavior (“PUB”) instrument that can be attached to an aerosol delivery device.

Abstract: Compositions and methods for detecting influenza are provided.

Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (BMC) from at least one chronically infected HBV individual in an 10 in vitroassay.

Abstract: Compositions and methods for detecting influenza are provided.

Abstract: A system for testing a vapor product with a mouthpiece that has a non-circular cross section includes an adaptor coupled to a neck portion of a filter pad holder. The adaptor includes a nose to receive the neck portion and an adaptor body coupled to the nose. An opening is defined by the adaptor body and the nose, the opening extending through the adaptor body and the nose and configured to receive the neck portion. A sealing member is configured to be received by the adaptor and the filter pad holder. The sealing member includes a sealing member nose configured to be received by the neck portion, and a sealing member body coupled to the sealing member nose and configured to be received by the opening. The sealing member body defines an orifice, the orifice extending through the sealing member body.

Abstract: A system for testing a vapor product with a mouthpiece that has a non-circular cross section includes an adaptor coupled to a neck portion of a filter pad holder. The adaptor includes a nose to receive the neck portion and an adaptor body coupled to the nose. An opening is defined by the adaptor body and the nose, the opening extending through the adaptor body and the nose and configured to receive the neck portion. A sealing member is configured to be received by the adaptor and the filter pad holder. The sealing member includes a sealing member nose configured to be received by the neck portion, and a sealing member body coupled to the sealing member nose and configured to be received by the opening. The sealing member body defines an orifice, the orifice extending through the sealing member body.

Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.

Abstract: A system for testing a vapor product with a mouthpiece that has a non-circular cross section includes an adaptor coupled to a neck portion of a filter pad holder. The adaptor includes a nose to receive the neck portion and an adaptor body coupled to the nose. An opening is defined by the adaptor body and the nose, the opening extending through the adaptor body and the nose and configured to receive the neck portion. A sealing member is configured to be received by the adaptor and the filter pad holder. The sealing member includes a sealing member nose configured to be received by the neck portion, and a sealing member body coupled to the sealing member nose and configured to be received by the opening. The sealing member body defines an orifice, the orifice extending through the sealing member body.

Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.

Abstract: A strain sensor system emits coarse interrogation signals of different frequencies during a coarse scan while an RF resonant sensor and/or an RF interrogator moves relative to the other. The sensor emits responsive RF signals within a frequency range of a frequency of interest of the sensor. The controller identifies the frequency of interest based on receipt of the responsive signals. The interrogator emits fine interrogation signals of different frequencies during a fine scan subsequent to the coarse scan. The fine signals are emitted at frequencies within a frequency band on both sides of the frequency of interest. The sensor emits responsive RF signals and the controller identifies a center frequency of the RF resonant sensor based on receipt of the responsive signals.

Abstract: Compositions and methods for detecting influenza are provided.

Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (BMC) from at least one chronically infected HBV individual in an 10 in vitroassay.

Abstract: Compositions and methods for detecting influenza are provided.

Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.

Abstract: A method of determining a cause of a performance deficiency of a vehicle may include: Determining whether the vehicle is operating in a defined load condition; comparing an actual vehicle performance parameter with a predetermined baseline performance parameter for the defined load condition; comparing a plurality of key indicator values of the vehicle with a predetermined specification for each of the plurality of key indicator values; concluding that the performance deficiency is the result of a mechanical condition of the vehicle when at least one of the key indicator values is outside of the predetermined specification for a corresponding key indicator value and when the actual vehicle performance parameter is outside of the predetermined baseline performance parameter; and concluding that the performance deficiency is the result of an operational condition when none of the key indicator values is outside of the predetermined specification for the corresponding key indicator value and when the actual vehi